Navigation Links
Charting the epigenome
Date:4/17/2008

n since we still have a very poor understanding of the genome-wide regulation of methylation and its effect on the transcriptome, explains postdoctoral researcher and co-first author Ryan Lister, Ph.D.

The transcriptome encompasses all RNA copies or transcripts made from DNA. The bulk of transcripts consists of messenger RNAs, or mRNAs, that serve as templates for the manufacture of proteins but also includes regulatory small RNAs, or smRNAs. The latter wield their power over gene expression by literally cutting short the lives of mRNAs or tagging specific sequences in the genome for methylation.

But before Lister could start to unravel the multiple layers of epigenetic regulation that control gene expression, he had to pioneer new technologies that allowed him to look at genome-wide methylation at single-base resolution and to sequence the complete transcriptome within a reasonable timeframe.

Collaborating scientists at the ARC Centre of Excellence in Plant Energy Biology at the University of Western Australia in Perth developed a powerful, web-based genome browser, which played a crucial role in unlocking the information hidden in the massive datasets.

Cells employ a whole army of enzymes that add methyl groups at specific sites, maintain established patterns or remove undesirable methyl groups. When Lister and his colleagues compared normal cells with cells lacking different combination of enzymes they discovered that cells put a lot of effort in keeping certain areas of the genome methylation-free.

On the flipside, the Salk researchers found that when they knocked out a whole class of methylases, a different type of methylase would step into the breach for the missing ones. This finding is relevant for a new class of cancer drugs that work by changing the methylation pattern in tumor cells.

You might succeed in removing one type of methylation but end up with increasing a different type, says Ecker. But ve
'/>"/>

Contact: Gina Kirchweger
kirchweger@salk.edu
858-453-4100 x1340
Salk Institute
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. $10 million gift to support cutting-edge epigenome center at USC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2015)... -- New Market Research Reports Title Global ... 2020 has Been Added to GrandViewReseach.com Report Database ... reach USD 5.10 billion by 2020, according to a ... help identify the site of tissue damage in case ... in medical imaging applications. They have been extensively used ...
(Date:2/5/2015)... VIEW, Calif. , Feb. 3, 2015 /PRNewswire/ ... printer technology, demand from industries such as consumer ... global market for surface mount technology (SMT) screen ... equipment to automatic control will push the adoption ... dispensers will remain steady as glue dispensers are ...
(Date:1/22/2015)... MELBOURNE, Fla. , Jan. 13, 2015  Today, ... wearable technology, launched its crowdfunding campaign on Fundable, ... accelerate the build of production capacity to meet ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
Breaking Biology News(10 mins):IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2
... - The growth in China,s carbon dioxide (CO2) emissions ... stabilizing atmospheric greenhouse gases even more difficult, according to ... California, Berkeley, and UC San Diego. Previous estimates, ... Change, say the region that includes China will see ...
... Research Prize and Medal will be awarded to Philip R. ... of Overseers and NJIT President Robert A. Altenkirch on March ... Solar-Terrestrial Research which has led a five-year project to build ... Observatory (BBSO), Big Bear Lake, CA. First light ...
... was not geographically isolated 25 million years ago ... demonstrated by researchers from the Laboratoire des Mcanismes ... Toulouse 3/IRD) and the Palobiodiversit et paloenvironnements laboratory ... results were obtained thanks to analyses of the ...
Cached Biology News:Alarming growth in expected CO2 emissions in China, finds UC analysis 2Alarming growth in expected CO2 emissions in China, finds UC analysis 3NJIT overseers to award NJIT physicist new medal and prize 2A fossilized giant rhino bone questions the isolation of Anatolia, 25 million years ago 2
(Date:2/27/2015)... (PRWEB) February 27, 2015 Immunovaccine ... and immunotherapy company, today announced that the U.S. ... for Fast Track designation and Phase I clinical ... conjunction with the mutual co-development agreement signed with ... Fast Track designation for the DPX-Survivac. , “We ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Cytokinetics, Incorporated ... on February 28 with patients and health care advocates ... for Rare Disease Day®. Rare Disease Day is ... calling attention to the special challenges faced by patients ... , “Cytokinetics is proud to stand alongside patients and ...
(Date:2/26/2015)... Feb. 26, 2015  23andMe, the leading personal genetics ... as Privacy Officer and Corporate Counsel. Black brings ... laws as well as health care regulations. As a ... be responsible for reviewing, updating and enhancing the company,s ... and abroad. She joined the company January 5, 2015 ...
(Date:2/26/2015)... LAUDERDALE, Fla. , Feb. 26, 2015 ... discussed growth priorities driven by key research advancements and ... segments at today,s Bank of America Merrill Lynch 2015 ... met the challenge of building grain supplies the last ... to continue at the pace of the last decade, ...
Breaking Biology Technology:Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 623andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 3DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 4DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 5
... parameter at the upcoming World ... Congress of Anesthesiologists Meeting, IRVINE, ... and Measure-Through Motion and Low Perfusion pulse,oximetry, announced that ... total hemoglobin (SpHb(TM)) and oxygen content,(SpOC(TM)) monitoring at the ...
... 25 Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ... first Phase 3 clinical trial with AZ-004 ... being developed for the treatment of,acute agitation ... Alexza,believes the novel, non-invasive nature and rapid ...
... Germany, February 25 t2cure, a clinical,stage biopharmaceutical ... cells, announced today that it has appointed,Dr. Petra ... pleased to have Petra join our company", said ... research and project,management will be of critical importance ...
Cached Biology Technology:Masimo Announces Continuous Noninvasive Total Hemoglobin 2Masimo Announces Continuous Noninvasive Total Hemoglobin 3Masimo Announces Continuous Noninvasive Total Hemoglobin 4Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 2Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 3Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 4Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 5Stem Cell Company t2cure Appoints Dr Rueck Head of Clinical Operations 2
... PRODUCT SPECIFICATIONS Form: White powder Assay: 1.5 - 2.0 Bleomycin ... 6.0 Loss On Drying: less than or equal to 6.0% ... A 2 : 55 - 70% B 2 : 25 ... or equal to 90% B 4 : less than or ...
... High Vacuum pumps deliver critical performance for ... ballast control optimizes pump performance to suit ... allows for convenient checking of proper oil ... of pumps is designed to work with ...
6 x Blend of rTth DNA Polymerase and Tli to provide optimized amounts of both 5-3 and 3-5 proofreading activity...
This spacer is required to use the Miniature FRENCH Pressure Cell (FA-003) with the Laboratory Press....
Biology Products: